NTRK1

(redirected from Tyrosine Kinase Receptor)
Also found in: Acronyms.

NTRK1

A gene on chromosome 1q21-q22 that encodes neurotrophic tyrosine kinase receptor type 1 (TrkA) which, after neurotrophin binding, phosphorylates itself (autophosphorylates) and members of the MAPK pathway. TrkA potently binds nerve growth factor (NGF) and is involved in differentiation and survival of neurons and in control of gene expression of enzymes involved in neurotransmitter synthesis. It is involved in cell differentiation and may play a role in specifying sensory neuron subtypes.

Molecular pathology
NTRK1 mutations are associated with congenital insensitivity to pain with anhidrosis, self-mutilating behaviour, mental retardation and cancer.
References in periodicals archive ?
The second gene identified, svh-2, encodes a tyrosine kinase receptor, homologous to the HGF receptor Met and the MSP receptor Ron (Fig.
Platelet tyrosine kinase receptors include the following members.
The PI3K/Akt pathway is a downstream target of the EGFR family and other tyrosine kinase receptors.
Tyrosine kinase receptors also are involved in cellular proliferation; the receptors are activated when the ligand comes into contact with 2 tyrosine protein chains in the cytoplasm of the targeted cell, creating a dimer.
EGFR (also called erbB1) is the first member of a closely related group of tyrosine kinase receptors known as the erbB family, the remaining three being erbB2, erbB3 and erbB4.
today announced the presentation of the abstract "CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in preclinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib" at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles, CA.
The protein product of the c-Met oncogene is the tyrosine kinase receptor for hepatocyte growth factor (HGF), and Compugen has discovered soluble variants of this receptor.
Vascular endothelial growth factor (VEGF) is a protein secreted by tumor cells which triggers angiogenesis (new blood vessel formation) by binding to and activating the signaling of the Flk-1/KDR tyrosine kinase receptor.
5,747,651 to the Company for antibodies against the extracellular portion of the tyrosine kinase receptor KDR/FLK-1.
ImClone Systems' lead anti-angiogenesis compound is a monoclonal antibody that inhibits the tyrosine kinase receptor known as KDR/FLK-1, located on tumor-associated capillary blood vessels.
Anti-flk-1 is a monoclonal antibody that blocks a key tyrosine kinase receptor, FLK-1/KDR, located on tumor-associated vascular endothelial cells.
The data further demonstrated that DC101 blocks a key tyrosine kinase receptor (FLK-1/KDR) located on the tumor associated vascular endothelial cells.

Full browser ?